Clinical Trial

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Study acronym: (DeLLphi-310)
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Protocol Amendment History 4 changes
notable Enrollment reduced: 200 -> 29 participants 2026-05-21
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-23
notable Primary completion pushed: 2031-04-23 -> 2031-06-23 2026-04-23
minor Completion pushed: 2031-04-23 -> 2031-06-23 2026-04-23
Trial Details
NCT Number NCT06898957
Lead Sponsor Amgen
Collaborators: MediLink
Conditions Small Cell Lung Cancer
Enrollment 29 participants
Start Date 2025-05-16
Primary Completion 2031-06-23 (estimated)
Study Completion 2031-06-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-20